The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; Novartis; Pfizer; Pfizer; Roche Pharma AG; Seagen; SOMATEX
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; MSD Oncology; MSD Oncology; Novartis; Pfizer; Roche Pharma AG; Seagen; Somatex
Travel, Accommodations, Expenses - Celgene; Novartis; Pfizer
CANKADO PRO-React eHealth support in patients with HR+ HER2- metastatic breast cancer receiving palbociclib and endocrine therapy and the affect on time to deterioration of quality of life: Primary outcome analysis of the multicenter randomized PreCycle trial.
 
Nadia Harbeck
Stock and Other Ownership Interests - West German Study Group
Honoraria - Amgen; AstraZeneca; Daiichi-Sankyo; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Seagen; Viatris; Zuelligpharma
Consulting or Advisory Role - Gilead Sciences; Novartis; Roche/Genentech; Sandoz; Seagen; West German Study Group (I)
Speakers' Bureau - EPG Communication; Medscape; Springer Healthcare
Research Funding - AstraZeneca (Inst); Lilly (Inst); MSD (Inst); Roche/Genentech (Inst)
 
Peter A. Fasching
Honoraria - Agendia; AstraZeneca; BionTech (Inst); Cepheid (Inst); Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst); Roche
 
Rachel Wuerstlein
Consulting or Advisory Role - Agendia; Amgen; Aristo; AstraZeneca; Celgene; Clovis Oncology; Daiichi Sankyo Pharmaceutical; Eisai; Exact Sciences; Genzyme; Gilead Sciences; GlaxoSmithKline; Hexal; Lilly O.; Medstrom Medical; MSD; Mundipharma; Mylan; NanoString Technologies; Novartis; Odonate Therapeutics; Palleos; Paxman; Pfizer; Pierre Fabre; PINK; Puma Biotechnology; RIEMSER; Roche; Sandoz/Hexal; Seagen; Stemline Therapeutics; Tesaro; Teva; Veracyte
Other Relationship - Aurikamed; ClinSol; FOMF; Ludwig Maximilian University of Munich; Ludwig Maximilian University of Munich; MCI Breast Cancer Symposium; MedConcept; Pomme Med
 
Tom Degenhardt
No Relationships to Disclose
 
Diana Lüftner
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo Pharmaceutical; Gilead Sciences; GlaxoSmithKline; L'Oreal; Lilly O.; Novartis; Pfizer; Seagan
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo Pharmaceutical; Gilead Sciences; GlaxoSmithKline; L'Oreal; Lilly O.; Novartis; Pfizer; Seagen
Speakers' Bureau - Amgen; AstraZeneca; Daiichi Sankyo Pharmaceutical; Gilead Sciences; GlaxoSmithKline; L'Oreal; Lilly O.; Novartis; Pfizer; Seagan
Research Funding - Novartis (Inst)
Expert Testimony - Amgen; AstraZeneca; Daiichi Sankyo Pharmaceutical; Gilead Sciences; GlaxoSmithKline; L'Oreal; Lilly O.; Novartis; Pfizer; Seagan
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Daiichi Sankyo Pharmaceutical; Gilead Sciences; GlaxoSmithKline; L'Oreal; Lilly O.; Novartis; Pfizer; Seagan
 
Ronald E. Kates
Honoraria - Amgen (I); Celgene (I); Genomic Health (I); NanoString Technologies (I); Novartis (I); Pfizer (I); Roche (I)
Consulting or Advisory Role - Agendia (I); AstraZeneca (I); Celgene (I); Daiichi Sankyo (I); Lilly (I); Merck Sharp & Dohme (I); Novartis (I); Odonate Therapeutics (I); Pfizer (I); Roche/Genentech (I); Sandoz (I); Seagen (I)
 
Johannes Schumacher
No Relationships to Disclose
 
Philip Raeth
No Relationships to Disclose
 
Oliver Hoffmann
Consulting or Advisory Role - AstraZeneca; Celgene; Daiichi Sankyo Pharmaceutical; Gilead Sciences; Hexal; Lilly O.; MSD; Novartis; Pfizer; RIEMSER; Roche; Seagan
 
Ralf Lorenz
No Relationships to Disclose
 
Thomas Decker
No Relationships to Disclose
 
Mattea Reinisch
No Relationships to Disclose
 
Thomas Göhler
No Relationships to Disclose
 
Peter Staib
Honoraria - Abbvie; Amgen; AstraZeneca; BMS GmbH & Co. KG; Celgene; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche Pharma AG
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BMS GmbH & Co. KG
Speakers' Bureau - Abbvie; Amgen; AstraZeneca; BMS GmbH & Co. KG; Pfizer; Roche Pharma AG
Research Funding - Abbvie; Celgene; Novartis; Roche
Travel, Accommodations, Expenses - Abbvie; AstraZeneca
Other Relationship - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BMS GmbH & Co. KG (Inst); Eisai Germany (Inst); Gilead Sciences (Inst); Incyte (Inst); Ipsen (Inst); Janssen Oncology (Inst); Lilly Medical (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche Pharma AG (Inst); Takeda (Inst)
 
Oleg Gluz
Honoraria - AstraZeneca; Celgene; Genomic Health; Lilly; MSD; NanoString Technologies; Novartis; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; Amgen; Daiichi Sankyo; Genomic Health; Gilead Sciences; Lilly; Merck Sharp & Dohme; MolecularHealth; Pfizer; Pierre Fabre; Roche; Seagen
Travel, Accommodations, Expenses - Daiichi Sankyo; Roche
 
Timo Schinkoethe
Leadership - CANKADO
Stock and Other Ownership Interests - CANKADO
 
Marcus Schmidt
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; SeaGen
Consulting or Advisory Role - AstraZeneca; BioNTech; Daiichi Sankyo/Astra Zeneca; Eisai; Lilly; MSD Oncology; Novartis; Pantarhei Bioscience; Pfizer; Pierre Fabre; Roche; SeaGen
Research Funding - AstraZeneca (Inst); BioNTech (Inst); Genentech/Roche (Inst); Novartis (Inst); Pantarhei Bioscience (Inst); Pfizer (Inst); Roche (Inst); SeaGen (Inst)
Patents, Royalties, Other Intellectual Property - EP 2390370 B1 A method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent; EP 2951317 B1 METHOD FOR PREDICTING THE BENEFIT FROM INCLUSION OF TAXANE IN A CHEMOTHERAPY REGIMEN IN PATIENTS WITH BREAST CANCER